Aquestive Therapeutics Overview

  • Status
  • Public

  • Employees
  • 147

Employees

  • Stock Symbol
  • AQST

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $3.47
  • (As of Friday Closing)

Aquestive Therapeutics General Information

Description

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Contact Information

Formerly Known As
MonoSol Rx
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • 30 Technology Drive
  • Warren, NJ 07059
  • United States
+1 (908)
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 30 Technology Drive
  • Warren, NJ 07059
  • United States
+1 (908)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aquestive Therapeutics Stock Performance

As of 20-Nov-2026, Aquestive Therapeutics’s stock price is $3.47. Its current market cap is $435M with 126M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.47 $3.71 $2.93 - $6.74 $435M 126M 2.41M -$0.64

Aquestive Therapeutics Financials Summary

As of 30-Sep-2026, Aquestive Therapeutics has a trailing 12-month revenue of $48.8M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 541,660 700,453 283,570 154,990
Revenue 48,837 44,545 57,561 50,583
EBITDA (66,883) (70,503) (30,053) (15,139)
Net Income (79,277) (83,784) (44,137) (7,870)
Total Assets 119,327 160,425 101,424 57,418
Total Debt 58,772 42,481 38,004 33,319
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Aquestive Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Aquestive Therapeutics‘s full profile, request access.

Request a free trial

Aquestive Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiate
Drug Delivery
Warren, NJ
147 As of 2025

San Diego, CA
 

Gentilly, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Aquestive Therapeutics Competitors (45)

One of Aquestive Therapeutics’s 45 competitors is Crinetics Pharmaceuticals, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Crinetics Pharmaceuticals Formerly VC-backed San Diego, CA
Sanofi Corporation Gentilly, France
Vanda Pharmaceuticals Formerly VC-backed Washington, DC
Novartis Corporation Basel, Switzerland
Cipla Corporation Mumbai, India
You’re viewing 5 of 45 competitors. Get the full list »

Aquestive Therapeutics Patents

Aquestive Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260108458-A1 Methods of administering enhanced delivery epinephrine and prodrug compositions to treat allergy Pending 23-Oct-2024
WO-2026090387-A1 Methods of administering enhanced delivery epinephrine and prodrug compositions to treat allergy Pending 23-Oct-2024
US-20260108422-A1 Pharmaceutical film storage and dispenser device Pending 21-Oct-2024
WO-2026090119-A1 Pharmaceutical film storage and dispenser device Pending 21-Oct-2024
US-20260027045-A1 Methods of administering enhanced delivery epinephrine and prodrug compositions Pending 23-Jul-2024 A61K9/006
To view Aquestive Therapeutics’s complete patent history, request access »

Aquestive Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aquestive Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Aquestive Therapeutics‘s full profile, request access.

Request a free trial

Aquestive Therapeutics Investments (4)

Aquestive Therapeutics’s most recent deal was a Corporate Asset Purchase with Aquestive Therapeutics (U.S. Patent for Multifunctional Single Layer Film Drug Delivery Technology). The deal was made on 20-Dec-2012.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Aquestive Therapeutics (U.S. Patent for Multifunctional Single Layer Film Drug Delivery Technology) 20-Dec-2012 Corporate Asset Purchase Buildings and Property
Adept Polymers 29-May-2007 Buyout/LBO Other Materials
Stanelco (Certain Equipment and Intellectual Property) 29-May-2007 Buyout/LBO Other Containers and Packaging
RespondTV 26-Jul-2000 Later Stage VC Social Content
To view Aquestive Therapeutics’s complete investments history, request access »

Aquestive Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Aquestive Therapeutics’s complete esg history, request access »

Aquestive Therapeutics Exits (1)

Aquestive Therapeutics’s most recent exit was on 26-Jul-2000 from RespondTV. The exit was categorized as with 8 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
RespondTV 26-Jul-2000 Completed
  • 8 buyers
To view Aquestive Therapeutics’s complete exits history, request access »

Aquestive Therapeutics FAQs

  • Where is Aquestive Therapeutics headquartered?

    Aquestive Therapeutics is headquartered in Warren, NJ.

  • What is the size of Aquestive Therapeutics?

    Aquestive Therapeutics has 147 total employees.

  • What industry is Aquestive Therapeutics in?

    Aquestive Therapeutics’s primary industry is Drug Delivery.

  • Is Aquestive Therapeutics a private or public company?

    Aquestive Therapeutics is a Public company.

  • What is Aquestive Therapeutics’s stock symbol?

    The ticker symbol for Aquestive Therapeutics is AQST.

  • What is the current stock price of Aquestive Therapeutics?

    As of 20-Nov-2026 the stock price of Aquestive Therapeutics is $3.47.

  • What is the current market cap of Aquestive Therapeutics?

    The current market capitalization of Aquestive Therapeutics is $435M.

  • What is Aquestive Therapeutics’s current revenue?

    The trailing twelve month revenue for Aquestive Therapeutics is $48.8M.

  • Who are Aquestive Therapeutics’s competitors?

    Crinetics Pharmaceuticals, Sanofi, Vanda Pharmaceuticals, Novartis, and Cipla are some of the 45 competitors of Aquestive Therapeutics.

  • What is Aquestive Therapeutics’s annual earnings per share (EPS)?

    Aquestive Therapeutics’s EPS for 12 months was -$0.64.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process